STL Index for: Minocycline

This guide will help you navigate the benefits of recent advancements in topical drug formulations and delivery systems. These innovations address limitations seen in older formulations, ensuring efficient and uniform delivery of active ingredients to target areas, improving patient acceptability, and enhancing treatment outcomes.

Sarecycline is a novel antibiotic that has shown significant promise in acne treatment due to its narrow-spectrum activity and weight-based dosing.

This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)

A variety of new skin treatments introduced in 2019.

This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)

Vitiligo is a psychosocially debilitating disease requiring a multidisciplinary approach to treatment. Patients should be made aware of all of the options available geared at repigmentation and depigmentation prior to formulating a treatment plan.

In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.

An increasing body of research indicates that dietary change may serve as a component of therapy for certain skin conditions. This includes conditions such as acne, atopic dermatitis, aging skin, psoriasis, and rosacea. This article takes a high level overview of the role that diet may play in these conditions.

Acne is among the most common dermatological conditions seen in primary care. In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.

Rosacea is a common, chronic cutaneous condition that affects the face. Various conventional and emerging therapies for rosacea are reviewed.

Administration of antibiotics, often for prolonged periods, has become the standard of care for acne. The authors provide current evidence to suggest that dermatologists should consider a departure from standard operating procedure by curtailing, if not discontinuing, the routine and regular use of antibiotics for acne.

Propionibacterium acnes (P. acnes) is an anaerobic bacteria implicated in the pathogenesis of acne. Current treatment guidelines offer strategies to limit the potential for resistance while achieving optimal outcome in the management of inflammatory and non-inflammatory acne.

Minocycline is a tetracycline antibiotic, which is often used for acne treatment for its anti-bacterial and anti-inflammatory effects. The mechanism of action, side-effects, and drug interactions are discussed.

Minocycline is a tetracycline antibiotic which is used for acne treatment. This article provides an overview of minocycline, side-effects, brands, and drug interactions are discussed.

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.

Suitable and unsuitable patient profiles for minocycline is discussed in this article. Important takeaways from clinical experience with minocycline is also in this article.

Dermatological and non-dermatological indications for minocycline ((Minocin®, Dynacin®, Vectrin®) are discussed in depth in this article.

Minocycline antibiotics are used to treat acne, rosacea, and perioral dermatitis. Considerations like appropriate dosing, cost of treatments, and patient compliance issues are discussed as well as efficacy.

Side effects, safety and risks of Minocycline (Minocin, Dynacin, Vectrin) are discussed in this article. Topics include drug interactions, bacterial resistance, as well as other adverse effects.

Rosacea is a common condition that affects people of all races. More aggressive and innovative uses of existing oral agents have resulted in novel therapeutic approaches, which can provide long-term therapy and sustained remission.

Acne is a multifactorial disease of the pilosebaceous unit in the skin. Four contributing pathogenic factors need to be elucidated and include excess sebum production, follicular hyperkeratinization, colonization of the pilosebaceous unit by Propionibacterium acnes.

Bullous pemphigoid (BP) is the most frequently occurring autoimmune blistering disease in Europe and North America. Although it is primarily a disease of the elderly, children and young adults can also develop it.

Treatment objectives and pharmacoeconomic considerations are important when developing guidelines that are effective and rational. Canadian Acne Treatment Guidelines were last published in 1995. New guidelines were recently developed to incorporate therapeutic advances and data from more recent studies.